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Research
Australian states between 9 April 2001 and 31 July 2001
Main outcome measures:  Frequency of anaemia (haem
enrolment and over ensuing 6 m nths, by tumour type,
anaemia treatment and “trigger” Hb level for this treatm
Results:  Participants had median age 60 years, and 61%
enrolment was 35% (199/562), with 78% of these 199 haABSTRACT
Objective:  To evaluate the frequency and management of anaemia in Australian adults with 
solid and haematological malignancies.
Design:  6-month observational, prospective, multicentre study.
Participants:  694 patients recruited from outpatient oncology clinics in 24 hospitals in five 
.
oglobin [Hb] level < 120 g/L) at 
 disease status and cancer treatment; 
ent.
 were women. Prevalence of anaemia at 
ving mild anaemia (Hb, 100–119 g/L). 
Frequency of anaemia (either present at enrolment or developing during the study) was 57% 
overall (323/566), and varied with tumour type, from 49% (lymphoma/myeloma) to 85% 
(urogenital cancer). Patients who received radiotherapy either in combination or concomitant 
with chemotherapy were more likely to have anaemia (73%) than those receiving chemotherapy 
alone (58%) (P= 0.004). Of all chemotherapy patients not anaemic at enrolment, 23% developed 
anaemia by the second monthly follow-up. Independent predictors for anaemia in chemotherapy 
patients were low baseline Hb level (odds ratio [OR], 5.4; 95% CI, 2.7–10.9) and use of platinum 
chemotherapeutic agents (OR, 4.8; 95% CI, 2.1–11.4) (P< 0.001). Anaemia was treated in 41% of 
patients with anaemia at enrolment — by transfusion (36%), iron (5%) and erythropoietic agents 
(2%). Frequency of anaemia treatment varied between tumour types, from 19% (breast cancer) to 
60% (leukaemia). The mean “trigger Hb” for initiating transfusion was 95 g/L.
Conclusions:  Anaemia is prevalent among Australian patients with cancer managed in hospital 
oncology units. Its management varies between tumour types. Many patients do not receive 
MJA 2005; 182: 453–457
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glo
12A emia (generally defined as haemo-bin concentration [Hb] below0g/L) is a common problem in
patients with cancer. Its causes are multifac-
torial,1,2 and its incidence depends on factors
such as type of malignancy, disease duration
and treatment regimen.1 Anaemia has numer-
ous physical effects which can greatly affect
quality of life in patients with cancer. How-
ever, it is difficult to accurately determine its
incidence and frequency from the literature
because of its widely varying definitions.3
The Australian Cancer Anaemia Survey
(ACAS) was initiated to create a “snapshot”
database documenting prevalence, incidence,
frequency and management of anaemia in the
adult cancer population attending oncology
departments in Australia, and to identify
patient and treatment characteristics associ-
ated with anaemia. ACAS was a prospective
multicentre survey run in parallel with the
European Cancer Anaemia Survey (ECAS),
conducted in 24 European countries.4
METHODS
Participants
Participants were recruited from consecutive
patients attending outpatient clinics of
oncology departments in 24 hospitals in five
Australian states between 9 April and 31
July 2001. Patients were eligible if they:
• were aged  18 years;
• had a diagnosis of at least one of the
following malignancies: breast, colorectal,
lung, urogenital, ovarian, cervical, head and
neck, pancreas, unknown primary, non-
Hodgkin’s lymphoma, Hodgkin’s disease,
myeloma, chronic lymphoid leukaemia,
acute myeloid leukaemia or acute lympho-
blastic leukaemia; and
• were scheduled to receive or were cur-
rently receiving chemotherapy, radiotherapy
or combined modality treatment, or were in
follow up.
Patients were excluded if they were
receiving experimental treatments or were
unable to have regular haematological
assessments. All participants provided writ-
ten consent after receiving a full explanation
of the survey.453
RESEARCHProtocol
The study was a prospective, multicentre
survey intended to track anaemia and its
management. Consenting participants were
followed up for 6 months after enrolment, at
approximately monthly intervals.
All data were recorded by a research nurse
and were managed centrally by an independ-
ent company, The Epsilon Group (Charlottes-
ville, Va, USA). This company also performed
all statistical analyses of the data.
Data recorded at enrolment were: demo-
graphic details, disease status, previous
treatment for cancer, treatment for anaemia
in the 30 days before enrolment, weight,
World Health Organization (WHO) per-
formance status (a global assessment of abil-
ity for self care and ambulation),5 and
results from a full blood examination. Data
recorded at subsequent visits were: treat-
ment status, treatment regimen, blood
parameters, transfusions, erythropoietic
agent and iron therapy administered, per-
formance status and weight.
The timing of data collection depended
on the cancer treatment being administered.
Patients about to receive treatment provided
enrolment data before the treatment began.
Those receiving chemotherapy, either alone
or simultaneously with radiotherapy, pro-
vided enrolment data at the end of a treat-
ment cycle, and further data at the end of
each subsequent treatment cycle, for a max-
imum of six cycles. Those receiving radio-
therapy alone provided enrolment data 3–6
weeks after radiotherapy began, on its com-
pletion, and at each subsequent visit.
Patients not currently receiving treatment
provided data at each follow-up visit (maxi-
mum once per month).
For analysis of anaemia frequency by can-
cer treatment, patients were categorised as:
chemotherapy only; radiotherapy only; con-
comitant chemoradiotherapy (chemother-
apy and radiotherapy administered
simultaneously); combination therapy (both
chemotherapy and radiotherapy adminis-
tered, but not simultaneously); or follow-up
(patient had completed cancer treatment).
Definitions
Anaemia was defined as Hb level < 120 g/L,
and moderate–severe anaemia as Hb level
< 100 g/L. Prevalence of anaemia was
defined as the percentage of patients who
had anaemia at enrolment. Incidence was
defined as the percentage of patients who
developed anaemia during the study among
those who were non-anaemic at enrolment.
Anaemia frequency was defined as the per-
centage of patients who either had anaemia
at enrolment or developed it during the
study.
Statistical analysis
To ensure a valid sample across tumour
types, sampling was stratified by tumour
type. Statistical analyses were performed
using the Statistical Package for the Social
Sciences (SPSS), version 12.01.6 Descriptive
statistics were used to explore patient char-
acteristics and baseline haemoglobin con-
centrations. Differences between groups
were examined using t tests (for propor-
tions) or Mann–Whitney tests (for continu-
ous variables). Logistic regression was used
to model the incidence of anaemia.
The survey was approved by the ethics
committee at each institution.
RESULTS
A total of 727 patients were enrolled. As no
records were kept of patients who declined
to participate, the participation rate is
unknown. Of the 727 enrolled, 694 had
evaluable data (33 had inconsistent coding
of diagnoses). Their characteristics are
shown in Box 1.
1 Population characteristics compared between the Australian Cancer Anaemia 








Mean age in years (range) 59.7 (19–90) 59.0 (18–96) 66 (M), 64 (F)
Female sex 369 (61.2%) 7014 (56.4%) 40578 (45.9%)
Disease status
New diagnosis, no cancer treatment 127 (18.6%) 4433 (32.8%) -
New diagnosis, cancer treatment 238 (34.2%) 2966 (22.0%) -
Persistent or recurrent 258 (37.9%) 4684 (34.7%) -
Remission 63 (9.3%) 1417 (10.5%) -
Treatment status -
No treatment 185 (30.1%) 7211 (53.7%) -
Chemotherapy alone 396 (64.5%) 5265 (39.2%) -
Chemotherapy + radiotherapy 26 (4.2%) 362 (2.7%) -
Radiotherapy alone 7 (1.1%) 578 (4.3%) -
Tumour type -
Breast 186 (26.8%) 2923 (21.8%) 11886 (13.4%)
Colorectal 168 (24.4%) 2245 (16.7%) 12844 (14.5%)
Lymphoma/myeloma 152 (22.1%) 2179 (16.2%) 5416 (6.1%)
Lung 47 (6.8%) 1900 (14.1%) 8275 (9.4%)
Gynaecological 38 (5.5%) 1564 (11.6%) 2832 (3.2%)
Leukaemia 38 (5.5%) 601 (4.5%) 2516 (2.8%)
Urogenital 21 (3.1%) 810 (6.0%) 16603 (18.8%)
Head and neck 7 (1.0%) 625 (4.7%) 3398 (3.8%)
Other 31 (4.5%) 587 (4.4%) 24751 (28%)
WHO performance status§
0 254 (37.8%) 5248 (35.5%) -
1 320 (47.6%) 6418 (43.4%) -
2 74 (11.0%) 2439 (16.5%) -
3 23 (3.4%) 582 (3.9%) -
4 1 (0.1%) 86 (0.6%) -
* Numbers and percentages unless otherwise indicated. 
† Data were missing for: sex, 91; disease status, 13; treatment status, 80; tumour type, 6; and performance 
status, 22. ‡ Australian incidence (not prevalence) data for 2001.7 
§ Global assessment of ability for self care and ambulation, where 0 = fully active; 1 = restricted in physically 
strenuous activity but able to carry out light work or activities; 2 = ambulatory and capable of self care but 
unable to work; 3 = capable of only limited self care, confined to bed or chair > 50% of time; 4 = completely 
disabled, totally confined to bed or chair.5 M = male. F = female.454 MJA • Volume 182 Number 9 • 2 May 2005
RESEARCHPrevalence of anaemia
The prevalence of anaemia at the
time of enrolment (defined as
patients with a documented Hb
level < 120g/L) was 35% overall
(199/562). Prevalence varied by
tumour type, disease status and
treatment type (Box 2). It was
highest for patients with gynaeco-
logical tumours (65%) and for
those with persistent and recur-
rent disease (44%).
Most (78%; 156/199) patients
with anaemia had an Hb level of
100–119 g/L. Prevalence of mod-
erate–severe anaemia (Hb < 100g/
L) was 7.7% (43/562) overall and
was highest among patients with
leukaemia (20%), gynaecological
(18%) and urogenital (17%) can-




The f requency of  anaemia
(defined as patients who had
anaemia at enrolment or devel-
oped anaemia during the study
period) is shown in Box 3. Fre-
quency was 57% overall (323/
566), and 60% (249/418) and
50% (74/148) in patients with
solid and haematological malig-
nancies, respectively (“other”
tumour types were excluded). For
individual tumour types, fre-
quency varied from 49% for lym-
phoma/myeloma to 85% for
urogenital cancer.
Frequency of moderate–severe
anaemia (Hb < 100g/L) was 19% overall
(110/588), and was highest in urogenital
cancer (45%).
The frequency of anaemia was compared
between cancer treatment groups for the
594 patients with at least one data point
after enrolment (Box 3B). The group
receiving chemotherapy plus radiotherapy,
either concomitantly (8 patients) or in
combination (78 patients), was more likely
to have anaemia (73%; 63/86) than the
group receiving chemotherapy alone (58%;
263/455; P = 0.004; 95% CI, 5%–25%).
Patients who received chemotherapy alone
were more likely to have anaemia than
those in follow-up after treatment (58%
[263/455] v 29% [14/48]; P < 0.001; 95%
CI, 15%–43%).
Incidence of anaemia
The incidence of anaemia was defined as the
percentage of patients who were not anae-
mic at enrolment (311 patients) but devel-
oped anaemia during the survey (Box 2).
Overall incidence was 37% (114/311).
Of the 236 patients who received chemo-
therapy and did not have anaemia at enrol-
ment, 191 were evaluable at the second data
point (about 2 months from enrolment): 44
(23%) had developed anaemia, and three
(2%) had moderate–severe anaemia. Analy-
sis of these data by tumour type showed that
incidence of anaemia in patients with breast
cancer (23%; 13/57) was significantly lower
than in those with lung cancer (67%; 6/9;
P = 0.03; 95% CI, 5%–83%), but not differ-
ent from incidence in patients with lym-
phoma/myeloma (27%; 10/37; P =
0.65) or colorectal malignancies
(14%; 8/58; P = 0.22).
Incidence of anaemia throughout
the survey was higher among
patients who received chemother-
apy (36%; 85/236) than among the
follow-up group (not receiving
treatment) (17%; 5/30; P = 0.01;
95% CI, 4%–34%).
A logistic regression model was
used to identify the factors influenc-
ing the development of anaemia in
chemotherapy patients. Variables
analysed were low baseline Hb level
(120–134 g/L for men, 120–129 g/L
for women), age, sex, tumour type,
disease status, WHO performance
score and use of platinum-based
chemotherapy. For anaemia, low
baseline Hb level (adjusted odds
ratio [OR], 5.4; 95% CI, 2.7–10.9;
P < 0.001) and platinum-based
chemotherapy (adjusted OR, 4.8;
95% CI, 2.1–11.4; P < 0.001) were
found to be independent predictors.
For Hb level < 100 g/L, only use of
platinum-based chemotherapy was
found to be an independent predic-
tor (adjusted OR, 9.7; 95% CI, 2.7–
35.7; P = 0.001).
Anaemia and performance 
status
Of the 672 patients with WHO per-
formance scores at enrolment, 574
(85%) had a score < 2 (“able to
complete light work or activities”).
Performance scores were higher
(indicating greater disability) in
those with more severe anaemia;
scores  2 were found in 10% (34/
357) of those with Hb  120 g/L compared
with 20% (30/148) of those with Hb, 100–
119 g/L, and 34% (12/35) of those with Hb,
80–99 g/L (Spearman r, 0.20; P < 0.001).
Treatment of anaemia
Records as to whether anaemia was treated
during the ACAS were available for 573
patients (421 with a solid tumour and 152
with a haematological malignancy). Among
those with anaemia, 64% (208/323) were
not specifically treated for anaemia during
ACAS — 67% (167/249) of those with solid
tumours and 55% (41/74) of those with
haematological malignancies.
The frequency of anaemia treatment
during the ACAS differed between tumour
2 Prevalence of anaemia at enrolment and incidence 





Overall 199/562 (35%) 114/311 (37%)‡
By tumour type
Breast 50/149 (34%) 29/86 (34%)
Colorectal 44/143 (31%) 24/89 (27%)
Lymphoma and myeloma 37/122 (31%) 22/71 (31%)
Lung 13/33 (39%) 13/19 (68%)
Gynaecological 22/34 (65%) 6/11 (55%)
Leukaemia 14/30 (47%) 1/8 (13%)
Urogenital 9/18 (50%) 7/9 (78%)
Head and neck 2/6 (33%) 3/4 (75%)
Other 6/22 (27%) 9/14 (64%)
By disease status
Newly diagnosed, untreated 25/76 (33%) 19/44 (43%)
Newly diagnosed, treated 65/213 (31%) 46/132 (35%)
Persistent/recurrent disease 93/210 (44%) 42/99 (42%)
Remission 13/54 (24%) 6/34 (18%) 
By cancer treatment status
No treatment§ 15/61 (25%) 5/30 (17%)
Receiving treatment 184/501 (37%) 111/284 (39%)
Chemotherapy 147/413 (36%) 86/236 (36%)
Combination therapy¶ 31/71 (44%) 21/40 (53%)
Concomitant therapy** 4/13 (31%) 3/6 (50%)
Radiotherapy 2/4 (50%) 1/2 (50%)
* Anaemia was defined as haemoglobin level < 120 g/L.
† Percentage of non-anaemic patients at enrolment who developed 
anaemia during the survey.
‡ Population of patients with at least one data point after enrolment.
§ About to begin treatment (prevalence) or in follow-up (incidence).
¶ Combination therapy = patient received both chemotherapy and 
radiotherapy, but not simultaneously. 
** Concomitant therapy = chemotherapy and radiotherapy delivered 
simultaneously. MJA • Volume 182 Number 9 • 2 May 2005 455
RESEARCHtypes (Box 4). The proportion of patients
with breast cancer not treated for their
anaemia was 81% (73/90), significantly
greater than the proportion of patients
with lung cancer (41%; 13/32; difference =
40%; 95% CI, 20%–60%; P < 0.001) and
gynaecological cancer (52%; 15/29;
difference = 29%; 95% CI = 8%–50%;
P < 0.01).
Of the 176 patients with anaemia at
enrolment, 41% received at least one ther-
apeutic intervention for anaemia during
the survey period: 36% received a transfu-
sion; 5%, iron; and 2%, erythropoietic
agents. Even among the 39 with moder-
ate–severe anaemia at enrolment, 28%
received no anaemia treatment during the
survey.
The mean Hb “trigger” level for initiating
transfusion as treatment for anaemia was
95 g/L (SD, 19) and differed between
tumour types (Box 5). The mean trigger Hb
was significantly higher for colorectal
tumours than for lung tumours (P = 0.02)
and lymphoma/myeloma (P = 0.003), but
did not differ between patients receiving
chemotherapy and those receiving either
combination or concomitant chemotherapy
and radiotherapy.
DISCUSSION
Our survey found that anaemia (Hb < 120g/
L) was common among adults with cancer,
with 57% of patients either having anaemia
at enrolment or developing it during the
following 6 months and 19% either having
or developing moderate–severe anaemia
(Hb < 100g/L). Patients who received radio-
therapy as well as chemotherapy were more
likely to have anaemia (73%) than those
who received chemotherapy alone (58%) or
those in the follow-up category not receiv-
ing cancer treatment (29%). Despite the
high frequency of anaemia, 64% (208/323)
of anaemic patients received no specific
treatment for this during the survey.
The frequency of anaemia found in our
survey is consistent with previous reports of
cancer-related anaemia, irrespective of
whether patients were receiving treat-
ment.1,3 It is also comparable to the fre-
quency of anaemia observed in ECAS.4
The major limitation of our survey is selec-
tion bias, as only selected patients from hos-
pital oncology departments were included. It
is difficult to assess how well the ACAS
reflects the population with cancer in the
community. Indeed, there were some differ-
ences in the profile of tumour types between
the ACAS and incidence data for the total
Australian population with cancer.7 How-
ever, this comparison is limited. It would
have been optimum to compare prevalence
rather than incidence data, but no accurate
data exist on Australian cancer prevalence
according to disease type. Secondly, this kind
of comparison does not take into account
differences in disease stage, as patients with
more advanced cancers are more likely to be
treated in a hospital oncology department.
Interestingly, comparison of the ACAS and
the European Cancer Anaemia Survey
4 Frequency of anaemia treatment during ACAS by tumour type for patients 
who had anaemia at enrolment or developed it during the survey (n= 339)*























































(n = 76) (n = 59) (n = 32) (n = 29) (n = 15) (n = 17) (n = 5) (n = 16)
3 Frequency of anaemia during ACAS
Error bars indicate the standard error of the mean for total frequency. * Data were missing for 14 patients. † Data were missing for 8 patients. 
Concomitant therapy = chemotherapy and radiotherapy delivered simultaneously. 






























































(n = 149) (n = 121) (n = 42) (n = 36) (n = 27) (n = 20) (n = 7) (n = 22)
Mild anaemia (Hb, 100-119 g/L)
A: By tumour type (n = 588)* B: By treatment type (n = 594)✝
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RESEARCHshowed that patient profiles in the two set-
tings were similar (Box 1).
In the ACAS, patients with gynaecologi-
cal, urogenital and lung malignancies had
the greatest risk of developing anaemia.
These cancers are often treated with plati-
num-based chemotherapy,1 and indeed
this therapy and “low-normal” baseline Hb
level were independently predictive of
developing anaemia. Of note in the ACAS,
the rate of anaemia for myeloma/lym-
phoma was lower (49%) than reported in
the ECAS (73%), even after accounting for
proportional differences of lymphoma to
myeloma within this subgroup.4 Other
studies also report up to a 70% incidence
of anaemia in patients with lymphoma/
myeloma receiving treatment.8,9 It is diffi-
cult to explain our different finding, as
age, sex and anaemia treatment before
enrolment were comparable in the two
surveys.
Cancer treatment may play a major role in
the development of anaemia.1,10 This is
illustrated in the ACAS, as 23% of the
patients who were not anaemic at enrolment
and received chemotherapy developed anae-
mia by the second data point (about 2
months after enrolment). In addition, the
incidence of anaemia was higher in patients
receiving both chemotherapy and radiother-
apy compared with chemotherapy alone,
but we note that the chemotherapy group
was considerably larger than the combina-
tion group, which may have biased results.
Despite the high frequency of anaemia,
most patients with anaemia were not specif-
ically treated for it. The rates of treatment
for anaemia were similar between the ACAS
and ECAS surveys, for both solid malignan-
cies (33% and 39%, respectively) and hae-
matological malignancies (45% and 47%,
respectively).4 When treatment was given
during the ACAS, red cell transfusion was
the most common therapy, given to 36% of
patients with anaemia; 2% of treatments
involved an erythropoietic agent. In com-
parison, in the ECAS, transfusion was given
to 17% and erythropoietic agents to 15%.4
The mean Hb trigger level for initiating
transfusion in the ACAS was similar to the
trigger level in the ECAS (97 g/L).
Our survey was not able to assess whether
the treatment of anaemia was appropriate.
Although the current National Health and
Medical Research Council guidelines for
transfusion practice do not recommend
transfusion routinely above a Hb level of
70 g/L,11 these guidelines are not specifically
for patients with cancer.
Exogenous erythropoietic agents were
used rarely. These agents are recommended
to treat mild to moderate anaemia in cancer
patients by both the American Society of
Hematology/American Society of Clinical
Oncology and the European Organization for
Research and Treatment of Cancer.7,12 Fur-
ther, the Cochrane Review on this subject
concludes that such agents improve haemato-
logical response in patients with baseline Hb
level < 100 g/L. However, debate continues
on the impact of erythropoietic agents on
quality of life.13 This debate, along with the
fact that these agents are not currently reim-
bursed by the Pharmaceutical Benefits
Scheme in Australia for treatment of cancer-
related anaemia, probably contributed to
their low usage during ACAS.
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5 “Trigger” haemoglobin level for 
initiating treatment of anaemia 
“Trigger” haemoglobin 
level (g/L) 




Urogenital (n = 9) 98 88 27
Leukaemia (n = 10) 101 95 25
Lung (n = 19) 95 89 19
Breast (n = 19) 102 96 19
Head/neck (n = 1) 87 87 –
Colorectal (n = 28) 113 105 28
Lymphoma/
myeloma (n = 26)
93 85 19
Other (n = 4) 128 126 19MJA • Volume 182 Number 9 • 2 May 2005 457
